Revitope Oncology is developing a novel class of bispecific antibody therapeutics utilizing its proprietary TwoGATE™ technology, which employs dual antigen targeting to activate T cells exclusively on tumor cells. This approach addresses the challenge of "on-target, off-tumor" toxicity in traditional immunotherapies by ensuring that immune activation occurs only when both targeted antigens are present, thereby enhancing safety and efficacy in treating solid tumors.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer immunotherapies often struggle with "on-target, off-tumor" toxicity due to a lack of specificity, limiting their efficacy and safety in treating solid tumors. This can result in damage to healthy tissues and reduced therapeutic benefits for patients.
Solution
Revitope Oncology is developing a novel class of bispecific antibody therapeutics designed to address the limitations of existing immunotherapies. The company's TwoGATE™ technology platform employs dual antigen targeting to activate T cells exclusively on tumor cells, enhancing safety and efficacy. This approach utilizes a true "AND" gate mechanism, ensuring immune activation only occurs when both targeted antigens are present on the same tumor cell. Revitope's Guided Antibody Tumor Engager (GATE) Technology Platform incorporates additional mechanisms to limit T cell activation to cancer cells, eliciting a powerful immune response while minimizing the risk of toxicity. The modular design allows for the creation of novel therapies using various protein-based modules, including antibodies, cytokines, and immune cell engagers.
Target Audience
The primary target audience includes researchers and clinicians focused on developing safer and more effective immunotherapies for solid tumors.
Features
- TwoGATE™ technology platform for dual antigen targeting, increasing specificity to tumor cells
- Bispecific antibodies with each molecule encompassing half of the binding domain required for T-cell engagement
- Protease activation mechanism that ensures drug molecules remain inactive until they reach the tumor site
- Stabilizing domain attached to a half-life extension module
- T Cell Engaging Antibody Circuit (TEAC) technology platform exploits co-expressed tumor antigens
- Modular design allowing for combination of antibodies, cytokines, and other immune cell engagers